The perfect hemostatic material should be capable of rapidly controlling substantial hemorrhaging from visceral organs, veins, and arteries. Ideally, it should be biodegradable, biocompatible, easily applied, and inexpensive. Herein, taking advantages of sodium alginate (SA), carboxymethyl chitosan (CMC), and collagen, a degradable powdery hemostatic composite (SACC) was synthesized using emulsification and cross-linking technology. The morphology and structure of SACC were determined using Fourier transform infrared spectroscopy and scanning electron microscopy (SEM). This hemostatic material exhibited a typical generic sphere shape with narrow size distribution, rough surface, and satisfactory water absorption. Using in vitro bleeding and in vivo bleeding models (rat liver injury model and rat tail amputation model), it was shown that SACC had superior hemostatic actions compared to CMC and SA. Excellent cytocompatibility was proven during cytotoxicity tests and SEM observations. Histomorphological evaluation during the wound healing process proved the superior biocompatibility of SACC in a rat liver injury model. Biodegradability of SACC was demonstrated by immunofluorescence techniques both in vitro and in vivo. In summary, we have demonstrated the enormous potential of SACC, which has excellent hemostatic activity, biodegradability, and biocompatibility properties for use in clinical hemostasis applications.
Tumor removal should be the first treatment option for patients with small VSs and preserved hearing, especially for young patients with good hearing; retrosigmoid approach is an effective and safe approach for small VSs removal with excellent functional outcomes; better preoperative hearing predicted a higher rate of postoperative hearing preservation; patients without fundal extension were more likely to achieve hearing preservation than those with fundal extension, but no difference had been detected when retrosigmoid removal assisted with endoscope was performed; patients with small tumors originating from SVN were more likely to achieve hearing preservation compared with those with IVN-originating tumors.
The great majority of sporadic vestibular schwannomas (VSs) are due to the inactivation of the NF2 gene. In this study, we found age-dependent differences in the clinical parameters of sporadic VSs. Young patients were characterized by progressive tumour behaviours, including earlier onset of initial symptoms, shorter symptom duration and larger tumour size. An increased rate of “two-hits” of both NF2 alleles, usually by mutation and allelic loss, was observed in young cases compared to older, and this correlated with the loss of protein and mRNA expression. In contrast, the tumours with a single mutation (referred to as ‘one-hit’) exhibited obvious expression levels. Moreover, a mixture of merlin-expressing tumour cells and non-expressing tumour cells was observed in ‘one-hit’ schwannomas, suggesting that a subset of ‘one-hit’ tumour cells was present in these tumours. To mimic the growth promoting effects by the second hit, we performed lentivirus-mediated NF2 knockdown in the ‘one-hit’ schwannoma cultures. Following the loss of NF2 expression, schwannoma cultures demonstrated increased proliferation rates. Above all, we have identified a correlation between the NF2 status and the growth patterns of sporadic VSs. The treatment decision-making, microsurgery or “wait and scan” strategy, should be carried out according to the tumour’s genetic background.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.